Home > Insider Trading > Filing (0000899243-16-029181)

Filing Details

Accession Number:: 0000899243-16-029181
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-09-16 20:00:46
Reporting Period:: 2016-09-15

Filing Date:: 2016-09-16
Accepted Time:: 2016-09-16 20:00:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1285819	Omeros Corp	OMER	Pharmaceutical Preparations (2834)	911663741

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1472163	S. Marcia Kelbon	201 Elliott Avenue West Seattle WA 98119	Vp Patent And General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-09-15	16,000	$0.98	179,597	No	4	M	Direct
Common Stock	Disposition	2016-09-15	16,000	$10.91	163,597	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2016-09-15	16,000	$0.00	16,000	$0.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2016-12-11	No	4	M	Direct

Footnotes

Open market sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2014, and amended on May 13, 2016, which provided for the exercise and sale of options to purchase 175,000 shares of common stock that expire on December 11, 2016. The May 13, 2016 amendment to Ms. Kelbon's trading plan provided for the future exercise and sale of certain other series of the issuer's stock options. Under the plan, the options expiring on December 11, 2016 would be exercised and sold at fixed sale periods, price and numbers set at the time the plan was adopted in 2014 over a one-year period beginning in November 2015, with sale periods commencing approximately monthly and with approximately 15,900 such options to be exercised and sold in each sale period. This sale was the last scheduled sale of options expiring in 2016 under the plan. Consistent with applicable trading rules, Ms. Kelbon has had no further control over the terms or timing of sales under the plan.
(Continued from Footnote 1) A portion of the proceeds from the exercise of the options expiring on December 11, 2016 are being used to fund Ms. Kelbon's exercise of other series of the issuer's stock options and retention of the underlying shares, and may also be used to fund the payment of taxes incurred by the exercise of such options.
This transaction was executed in multiple trades at prices ranging from $10.69 to $11.08; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
The option vested and became exercisable in 48 equal monthly installments. The first installment became exercisable on November 1, 2005 and subsequent installments became exercisable on each monthly anniversary thereafter.